A Double-blind, Placebo-controlled Trial of Transdermal Fentanyl after Abdominal Hysterectomy

Analgesic, Respiratory, and Pharmacokinetic Effects

Alan N. Sandler, M.B., Ch.B., F.R.C.P.C.,* Alan D. Baxter, M.B., Ch.B., F.R.C.P.C.,† Joel Katz, Ph.D.,‡
Gideon Koren, M.D., F.R.C.P.C.,** Sandra Roger, R.N.,†† Kathryn Hull, R.N.,‡‡ Julia Klein, M.Sc.§§

Background: A randomized, double-blind, placebo-controlled trial was conducted to assess the analgesic, pharma-

okinetic, and clinical respiratory effects of 72-h application of two transdermal fentanyl (TTSF) patch sizes in patients undergoing abdominal hysterectomy.

Methods: TTSF patches releasing 50 µg/h (TTSF-50) or 75 µg/h (TTSF-75) fentanyl or placebo patches were applied to 120 women 2 h before abdominal hysterectomy under general anesthesia. Postoperatively, all patients had access to supplemental morphine using patient-controlled analgesia pumps. Each patient was attended continuously by a research nurse for 8 h on the night before surgery and for 8 h after patch application. The following data were collected: visual analog scale pain scores, supplementary analgesia, fentanyl plasma concentration (4-h intervals), continuous hemoglobin saturation (pulse oximetry), respiratory pattern (continuous respiratory inductive plethysmography), and adverse effects (nausea, vomiting, pruritus). Data analysis included analysis of variance, Kruskal-Wallis, and chi-squared. P < 0.05 was considered significant.

Results: There were no demographic differences among groups. Visual analog scale pain scores were significantly lower for the TTSF-75 group, and supplemental morphine was significantly decreased in the TTSF-75 group in the postanesthesia care unit and for both the TTSF-50 and the TTSF-75 group for 8-48 h postoperatively. Between 5 and 36 h, the TTSF groups had significantly increased abnormal respiratory pattern including apneic episodes (tidal volume of less than 100 ml for more than 15 s) and episodes of slow respiratory rate (less than 8 breaths/min persisting for more than 5 min) and significantly increased requirement for oxygen supplementation. Nine patients in the TTSF groups were withdrawn because of severe respiratory depression compared to none in the placebo group. No significant between-group differences were present in the incidence of nausea, vomiting, or pruritus. Although fentanyl plasma concentration was higher in the TTSF-75 group than in the TTSF-50 group, the differences were not significant. Fentanyl plasma concentration decreased significantly 48 h after patch application.

Conclusions: Application of TTSF patches 2 h preoperatively is associated with moderate supplementary opioid requirements for analgesia in the early postoperative period and ongoing opioid supplementation for at least 72 h. Although good analgesia is the result of this combination therapy, it is associated with a high incidence of respiratory depression requiring intensive monitoring, oxygen supplementation, removal of the TTSF patches in approximately 11% of the patients, and opioid reversal with naloxone in approximately
THE combination of the Transdermal Therapeutic System (TTS, Alza, Palo Alto, CA) with the lipid-soluble synthetic opioid fentanyl provided a simple, effective transdermal delivery system for a potent opioid analgesic. The system controls release of fentanyl to provide a continuous and steady supply of the opioid transdermally and maintains relatively predictable plasma concentrations of fentanyl without invasive procedures or special equipment. The variation in patient metabolic clearance and steady-state volume of distribution will determine the resulting steady-state plasma concentration in each subject. Drug delivery is increased by increasing the size of the active patch surface as each square centimeter delivers approximately 2.5 \( \mu g/h \) fentanyl. Thus, a 20-cm\(^2\) patch delivers 50 \( \mu g/h \) and a 30-cm\(^2\) patch 75 \( \mu g/h \). Earlier clinical studies documented the analgesic effectiveness of various sizes of TTSF patches (e.g., 50, 75, and 100 \( \mu g/h \)) for the treatment of postoperative pain after orthopedic, urologic, gynecologic, abdominal, and thoracic surgery. Most of these studies involved patch application of 24 h or less with a small number of studies assessing patch use over longer periods (up to 72 h). The choice of administered dose should result in fentanyl plasma concentrations that are safe in all patients, i.e., no risk of respiratory depression; this will result in incomplete analgesic efficacy in some patients because of pharmacokinetic variability. Thus, the supplementation of morphine (or other analgesics) is a fundamental component of the use of transdermal fentanyl patch in some patients. A common finding in previous studies was the requirement for supplementary analgesics in addition to the TTSF patch in the postoperative period. Despite using relatively low-dose TTSF patches that often required opioid supplementation, several investigators still reported a relatively low incidence of clinically significant respiratory depression in their patients receiving TTSF using mostly noncontinuous methods to measure respiratory depression. Therefore, we elected to further investigate the use of the TTSF patch to define the incidence and severity of clinically significant respiratory depression with its use. Thus, this study was undertaken to evaluate 50 and 75 \( \mu g/h \) TTSF used for 72 h after abdominal hysterectomy. Postoperative analgesia, supplementary opioid requirements using patient-controlled analgesia (PCA), serial plasma fentanyl concentration, and particularly intensive noninvasive continuous respiratory monitoring (pulse oximetry, respiratory inductive plethysmography) were measured for 84 h after surgery to determine the analgesic effectiveness and the respiratory effects of the TTSF patch.

Methods and Materials

Approval to carry out this study was obtained from the Toronto Hospital and Ottawa General Hospital Committees for Research on Human Subjects. All patients gave their written informed consent to participate before entering the study. The study was designed to be randomized, double-blind, and placebo-controlled.

Sample Size Estimation. Based on the results of previous studies, it was determined that, in a three-arm study comparing placebo, TTSF-50, and TTSF-75, a sample size of 40 patients per group would provide a type 1 error rate of 0.05 and a type 2 error rate of 0.1 (i.e., power of 90\%) to detect a mean difference in morphine use of 6 mg during the period from 12 to 24 h after TTS application. This difference applied to comparisons between each of the two active groups and the placebo group.

Patient Selection. Patients scheduled for abdominal hysterectomy were included in the study. Inclusion criteria were age 18–60 yr; ASA physical status 1 or 2; body weight 50–75 kg; no significant central nervous system, respiratory, cardiac, hepatic, or renal dysfunction; no previous allergies or adverse reactions with opioid analgesics; and no history of opioid or substance abuse.

Randomization and Blinding Procedures. Patients were randomly assigned to one of three groups, placebo, TTSF-50, or TTSF-75. Double-blinding was achieved by applying two unmarked patches to each patient, one of TTSF-50 size and the other of TTSF-75 size. Active patches containing fentanyl were indistinguishable from placebo patches.

Preoperative Assessment. The night before surgery, patients were familiarized with the visual analog scale (VAS) and were introduced to the PCA pump and instructed in its use. To provide baseline measurements for postoperative respiratory assessment, all subjects underwent a modified sleep study for 8 h on the preoperative night. Respiratory pattern was assessed continuously with respiratory inductive plethysmography (NIMS, Miami Beach, FL), and hemoglobin oxygen saturation (\( S_{PO2} \)) was continuously measured using pulse oximetry.
oximetry (Nellcor N-100, Nellcor, Hayward, Ca) while patients slept. Calibration and validation of the respiratory inductive plethysmograph—as well as its application in previous postoperative analgesic studies—have been described elsewhere. 

Respiratory rate (RR), episodes of apnea (tidal volume of less than 100 ml for more than 15 s), and episodes of slow RR (SRR, less than 8 breaths/min persisting for more than 5 min) were measured continuously and recorded in 5-min epochs. Patients were attended continuously by trained personnel during the entire 8-h preoperative and 84-h postoperative data collection periods. Respiratory pattern abnormalities were confirmed by the analysis of real-time respiratory inductive plethysmography output and direct observation of the patient. Revalidation (spirobag technique) was performed several times during the observation periods and recalibration instituted if the error was greater than 20%.

**Patch Application.** The patches were applied immediately below the clavicle on the right and left sides of the upper chest approximately 2 h before surgery. The time of patch application was taken as time 0 for all measurements.

**Anesthesia.** All patients received 10 mg oral diazepam 2 h preoperatively. Anesthesia was induced with sodium thiopental and maintained with 0.5 μg/kg sufentanil, oxygen/nitrous oxide, and isoflurane plus pancuronium for muscle relaxation. At the conclusion of surgery, muscle relaxation was reversed with neostigmine and atropine. With resumption of spontaneous breathing, the trachea was extubated, and the patient was transported to the postanesthesia care unit (PACU).

**Postoperative Management**

**Supplementary Analgesia.** The patches were left in situ for 72 h after application. Patients were monitored and data collected for the full 72 h period of patch application plus an additional 12 h after patch removal. Supplementary analgesia consisted of observer-administered morphine boluses in the PACU and PCA morphine upon transfer to the ward. In the PACU, if the patient spontaneously requested analgesia, a 2-mg dose of intravenous morphine was given. In addition, at 10-min intervals, the patient was asked, “Do you need pain relief?” If a positive response was given, a 2-mg intravenous dose of morphine was administered. The PCA pump (Abbott Life Care Infuser, Chicago, IL) was set to deliver a 1-mg bolus of morphine with a lockout time of 5 min. The total dose of morphine required during the past hour was recorded hourly.

**Postoperative Pain and Sedation Measurement.** A 10-cm VAS with 0 = no pain and 10 = worst pain imaginable, was used to assess pain intensity at rest and with movement. Pain was measured every 4 h unless the patient was asleep. A three-point sedation scale was recorded every 4 h unless the patient was asleep (0 = alert, oriented; 1 = drowsy, oriented; 2 = drowsy, disoriented). No more than 8 h was allowed to elapse between two consecutive measurements, which occasionally required waking the patient.

**Pharmacokinetic Analysis.** Immediately before the application of the TTS patches and every 4 h postoperatively, venous blood samples were drawn from a peripheral vein (via an indwelling heparinized cannula where possible) for plasma fentanyl assay. Plasma fentanyl concentrations were determined with a commercial radioimmunoassay kit (Janssen, Beerse, The Netherlands). In our laboratory, the assay is sensitive to 0.1 ng/ml, with intrassay and interassay coefficients of variation of 6.0% and 6.9%, respectively, at 1.0 ng/ml.

**Postoperative Respiratory Monitoring.** When the patient arrived in the PACU, respiratory inductive plethysmography and pulse oximetry monitoring was reinstituted and continued until the end of the study. Oxygen supplementation routinely was provided for the first 2 h in the PACU and then discontinued. If, at any time, respiration was judged to be inadequate (RR < 8 breaths/min × 3 episodes/h) and/or hemoglobin saturation was <90%, an arterial blood gas sample was analyzed. If SpO₂ persisted at <90%, supplementary oxygen was provided by face mask to provide SpO₂ > 90%. The TTS system was removed if RR was <8 breaths/min × 3 episodes/h for 2 consecutive h and/or SpO₂ was <90% and PaCO₂ was >55 mmHg. Removal of the TTS patches terminated the study for that patient. Respiratory monitoring, however, was continued for a further 12 h because of the fentanyl depot that develops intradermally with the TTS system and continues to maintain a plasma fentanyl concentration.² In the event of severe respiratory depression, naloxone was administered as required.

**Adverse Effects.** Nausea and vomiting were treated as needed with 25–50 mg intravenous diphenhydramine and/or 1 mg intravenous droperidol. Pruritus was treated with 50 mg intravenous diphenhydramine as needed. TTS attachment sites were assessed at regular intervals and at the time of removal for skin reactions.
### Data Analyses

Data are summarized as their mean value ± SEM (for parametric data) and as frequencies or percentages (for nonparametric variables) and were analyzed using one-way analysis of variance (ANOVA, e.g., demographic data) or chi-squared tests of significance, respectively. Data amenable to repeated-measures ANOVA (pain intensity at rest, pain intensity with movement, supplementary morphine, vital signs) were analyzed over time (in 4- or 12-h blocks) using treatment group and study site as factors, followed by linear contrasts or Tukey's test to compare pairwise differences when the overall ANOVA was significant. Overall apnea rate and SRR/h were analyzed using a one-way ANOVA for the entire 84-h period and again between 5 and 36 h postoperatively. When the overall ANOVA demonstrated a significant group effect, Tukey's test was used for pairwise comparisons between the groups. Nonparametric data were analyzed using chi-squared, with study site as stratum, or Fisher's exact test, when necessary. The strength of the linear relationship between plasma fentanyl concentration and respiratory parameters (mean RR, SRR/h, apnea rate) was evaluated by computing Pearson product moment correlation coefficients (r) for each group every 4 h after surgery. A simple comparison of average plasma fentanyl concentration across two periods, 28–48 and 52–72 h, was made for each dosing group, using the paired t test. P < 0.05 was considered statistically significant for all tests.

### Results

#### Patient Withdrawals

One hundred twenty patients were enrolled in the study, with 103 patients completing the study. Seventeen patients were withdrawn for the following reasons: Two patients did not undergo scheduled surgery, and the TTS patches were removed within 6 h of application with no adverse effects. One patient received 10 times the protocol dose of sufentanil intraoperatively and subsequently required removal of the TTS patch (3 h after application) and multiple doses of naloxone because of respiratory depression. Of the remaining 14 patients, 2 were withdrawn because of failure of respiratory monitoring equipment, 1 patient became frustrated with the respiratory monitoring regime and withdrew, 1 patient removed her patches 29 h after application, 1 patient developed pneumonia and was withdrawn, and 9 patients were withdrawn from the study because of respiratory depression (table 1). Six of the nine patients withdrawn because of respiratory depression were in the TTSF-75 group. The data from these 14 patients were included in all analyses up to the times at which they were withdrawn.

#### Demographic and Clinical Data

There were no significant differences between the three groups with respect to age (33–36 yr), weight (61–64 kg), duration of anesthesia (112–115 min), or duration of PACU observation period (169–184 min).

#### Postoperative Pain

Overall, VAS pain scores were significantly less for the TTSF-75 group at rest (P = 0.03) and with movement (P = 0.04) compared with the placebo group, but the TTSF-50 group did not differ significantly from the placebo group for either rest or movement pain. VAS pain scores were high in the early postoperative
period for all three groups (fig. 1). There was no significant difference between VAS pain scores at rest or with movement within each of the three groups.

Postoperative Morphine Consumption

PACU. The mean total observer-administered morphine requirements in the PACU was significantly less ($P = 0.04$) in the TTSF-75 group compared with the placebo group (TTSF-75 $17.0 \pm 1.4$ mg, TTSF-50 $18.4 \pm 1.4$ mg, placebo $21.9 \pm 1.7$ mg). Although the TTSF groups required less supplemental morphine per hour in the PACU than did the placebo group, this difference was only significant for the TTSF-75 group during the 3rd hour in the PACU (fig. 2).

Ward. The mean total PCA morphine requirements on the ward were significantly less for both TTSF groups (TTSF-75 $39.2 \pm 7.1$ mg, TTSF-50 $42.6 \pm 6.4$ mg, placebo $72.5 \pm 6.9$ mg; $P = 0.001$, TTSF-75, TTSF-50 vs. placebo). Similarly, the total postoperative supplemental morphine requirements (PACU + ward) were significantly less for the TTSF groups compared with placebo (TTSF-75 $56.7 \pm 7.9$ mg, TTSF-50 $61.2 \pm 6.7$ mg, placebo $94.4 \pm 7.7$ mg; $P = 0.0008$, TTSF-75, TTSF-50 vs. placebo). Between 8 and 48 h postoperatively the TTSF groups used significantly less morphine than the placebo group (fig. 2).

Respiratory Monitoring

There was no difference in the mean hourly apnea rate or in the number of episodes of SRR/h among the groups for the 8-h preoperative monitoring period (figs. 3 and 4). However, the apnea rate between 5 and 36 h after patch application was significantly higher for TTSF-75 group compared with the placebo group but not when compared with the TTSF-50 group ($P = 0.006$; fig. 3). In addition, within this period, the three groups differed significantly in the number of patients with mean hourly apnea rate of $<1$ or $>10$ ($P < 0.006$). Only 2 patients in the placebo group had a mean hourly apnea rate of $>10$, whereas 28 patients had a mean hourly apnea rate of $<1$. In contrast, 12 patients in the TTSF-75 group had a mean hourly apnea rate of $>10$, and 17 patients had a mean hourly apnea rate of $<1$. Twenty-one patients in the TTSF-50 group had a mean hourly apnea rate of $<1$, and 6 had a mean hourly apnea rate of $>10$. Similarly, there was a significant difference between the TTSF-75 and TTSF-50 groups compared with placebo in the mean hourly number of episodes of SRR between 5 and 36 h ($P = 0.005$; fig. 4). Significantly more patients in the TTSF-75 group had a mean of 3 or more SRR episodes/h (placebo $n = 5$, TTSF-75 $n = 22$; $P = 0.003$). Sixteen patients in the TTSF-50 group had a mean of 3 or more episodes of SRR/h.

The number of patients requiring supplementary oxygen according to study criteria was significantly different for the three groups ($P < 0.001$; fig. 5). Significantly more patients in the TTSF-75 group ($n = 25$) received oxygen supplementation when compared with the TTSF-50 ($n = 12$) and the placebo group ($n = 7$).
Oxygen supplementation was not necessary after 48 h (fig. 5). Significantly more patients in the TTSF groups required arterial blood gas sampling compared with the placebo group (placebo n = 12, TTSF-50 n = 24, TTSF-75 n = 25; P = 0.04), and mean PaCO₂ was significantly different in the TTSF-75 group compared with placebo (TTSF-75 PaCO₂ = 47 ± 1, placebo PaCO₂ = 42 ± 1; P = 0.04). There were no patient withdrawals due to adverse respiratory events in the placebo group, but three and six patients were withdrawn from the TTSF-50 and TTSF-75 groups, respectively, because of severe respiratory depression. Patient withdrawals for severe respiratory depression in the TTSF groups occurred within 5–32 h after patch application (table 1). Naloxone for respiratory depression reversal was not required for any patient in the placebo group, whereas two patients in the TTSF-50 and three patients in the TTSF-75 group were treated with naloxone (table 1).

**Adverse Effects**

There was no significant difference in the incidence of adverse effects (nausea and/or vomiting: placebo n = 19, TTSF-50 n = 23, TTSF-75 n = 23; pruritus: placebo n = 4, TTSF-50 n = 2, TTSF-75 n = 5; P = 0.4).

**Pharmacokinetic Analysis**

Eight hundred five blood samples (TTSF-50 n = 434, TTSF-75 n = 371) were analyzed for fentanyl concent-

---

**Fig. 3.** Mean apnea/h (apnea = 15 s + Vt < 100 ml). Between 5 and 36 h, mean apnea/h in the TTSF-75 group was higher than in the placebo group (P < 0.006). The downward-pointing arrow indicates removal of the TTSF patch.

**Fig. 4.** Mean hourly number of 5-min episodes of slow respiratory rate (SRR, <8 breaths/min for 5 min). There were significantly more episodes of SRR/h in the TTSF-50 and TTSF-75 groups compared with the placebo group between 5 and 36 h (P = 0.05). The downward-pointing arrow indicates removal of the TTSF patch.
plasma fentanyl concentration represents a 33% decrease from the mean plasma fentanyl concentration on the 2nd day. Area under the curve, 0–84 h (trapezoidal rule, mean data) for TTSF-75 was 103.8 ng·h·ml⁻¹ and for TTSF-50 was 76.1 ng·h·ml⁻¹. The ratio of area under the curve, TTSF-75:TTSF-50, is 1.4.

Figure 7 shows the correlation coefficients between plasma fentanyl concentration and mean RR, SRR/h, and mean hourly apnea rate for the TTSF-75 and TTSF-50 groups on a 4-hourly basis after surgery. With the exception of a few time points, there was no significant linear relationship between plasma fentanyl concentration and respiratory parameters. When Bonferroni’s type I error rate correction for multiple correlation coefficients (i.e., α = 0.05/number of tests) was used, no correlation coefficient reached statistical significance. These graphs indicate that, when data from all patients are used, there is no tendency for plasma fentanyl concentration to be significantly correlated with the three respiratory parameters.

Discussion

This study demonstrated that the TTSF patch (50–75 μg/h) provides dose- and time-dependent analgesic efficacy to patients undergoing abdominal hysterectomy. As in other studies, we found a reduced ongoing need for PCA supplementation in the TTSF groups. However,
Fig. 7. Pearson product-moment correlation coefficients (r) between plasma fentanyl concentration and the three respiratory parameters for the TTSF-50 and TTSF-75 groups every 4 h after surgery. Each point represents the correlation coefficient between plasma fentanyl concentration and one of the three respiratory parameters at a given time after surgery. *P < 0.05. (Note: Using Bonferroni type I error rate correction for multiple tests of significance, none of the correlation coefficients reached statistical significance.)

The respiratory depression observed was of a significant degree and gave rise to concern about patient welfare, in contrast to observations made with PCA alone.

The TTSF patch is a slow-onset, easy-to-use, noninvasive transdermal infusion device that produces plasma concentrations similar to those achieved with an intravenous infusion of fentanyl. The plasma concentration of fentanyl will be related to the degree of analgesia produced and the production of adverse effects, but in individual patients, analgesia and other opioid effects are modified by other factors, such as age, individual sensitivity, concomitant medications or other interventions, and underlying disease states. Fentanyl, like all opioids, has a relatively restricted clinically useful dose-response range that can be defined as the range between the minimally effective analgesic concentration (MEAC) and the highest tolerable analgesic concentration before the production of significant respiratory depression. Several studies using PCA or fentanyl infusions showed the MEAC for fentanyl to vary between 0.6 and 1.7 ng/ml. Individual patients, however, will vary in MEAC requirements over as much as a sixfold range. Clinically significant respiratory depression was measured in similar studies with plasma fentanyl concentrations of 1–3 ng/ml.

Pharmacokinetic Analysis

The peak plasma concentrations produced by TTSF-50 and TTSF-75 patches in this study are similar to those described in other TTSF patch studies. This report is the first large study to report pharmacokinetic data with a TTSF patch in place for 72 h. Mean fentanyl plasma concentration is significantly lower on the 3rd day (52–72 h) compared with the 2nd day (28–48 h) for both TTSF groups, indicating that both the 50-μg/h and the 75-μg/h patch did not provide steady-state plasma fentanyl concentration after 2 days of application. In the current study, although mean plasma fentanyl concentration was within the therapeutic range between 14 and 48 h after patch application, most patients in the TTSF...
groups required PCA morphine supplementation for satisfactory analgesia.

**Postoperative Analgesia and Morphine Supplementation**

A clear disadvantage of the TTSF system is the slow development of effective plasma concentration. Thus, in this study in which the TTSF patches were applied 2 h preoperatively and only modest doses of intraoperative opioid were administered, high pain scores and high morphine requirements were seen in the immediate postoperative period in the PACU for all three groups (figs. 1 and 2). At 12 h postoperatively, PCA morphine requirements for the TTSF groups were markedly decreased, reflecting fentanyl plasma concentration approaching analgesic concentrations. The placebo group (PCA only) maintained greater morphine requirements for the full 84 h. In addition, the placebo group characteristically did not achieve VAS scores less than 30% of maximum VAS. This finding is similar to what other studies found when patients use PCA. Other investigators reported similar findings to those found in this study, i.e., lower VAS scores (especially in those studies using 50–100-μg/h TTSF patches) and lower opioid supplementation in the TTSF groups. It is significant to note that the majority of the subjects in these studies and in ours required opioid supplementation despite the application of a TTSF patch.

**Respiratory Effects**

The rationale for the use of noninvasive continuous electronic monitoring systems to measure respiratory pattern and pulse oximetry in postoperative analgesic studies was documented elsewhere and validated in studies from our group and others. In general, the system provides a nondisturbing mechanism of observing and recording clinically significant respiratory depression in the clinical setting. The use of a nondisturbing system to measure respiratory pattern and hypoxemia allows study of the postoperative patient in a setting as close to real life as possible. Other useful techniques to measure opioid-induced respiratory depression, such as carbon dioxide-response tests, produce alertness and arousal that alter the conditions normally found in the postoperative patient. Catley et al. showed correlation between changes in ventilatory pattern and episodic oxygen desaturation when opioid analgesics are used postoperatively, thus demonstrating noninvasive monitoring techniques to be useful indicators of respiratory risk. In this study, we observed a dose-dependent increase in the apnea rate and episodes of SRR/h for each group as the dose of TTSF was increased (figs. 3 and 4). In addition, the number of patients with significant apnea rates, SRR episodes, and hypoxemia (i.e., requiring supplementary oxygen) increased significantly as the dose of TTSF was increased (fig. 5). Similarly, the number of patients requiring arterial blood gas analysis (on the basis of the criteria outlined above) was significantly greater among patients in the TTSF groups. The development of carbon dioxide retention increased as the dose of TTSF was increased (table 1). None of the patients in the three groups had evidence of sleep apnea or respiratory pattern abnormalities from the preoperative monitoring results. It was significant that 9 of 80 (11.3%) of the patients in the TTSF groups were withdrawn because of increasingly severe respiratory depression. On the basis of the findings in this study and in others, noninvasive monitoring systems of respiratory function, when coupled with pulse oximetry, provide as good an indicator of risk of respiratory depression in the clinical setting as is currently possible.

Respiratory depression following the use of the TTSF patch has not been examined systematically. Several investigators reported a low incidence of moderate to severe respiratory depression in previous studies. Respiratory depression was defined as RR < 8–10 breaths/min for the majority of these studies, and RR was measured intermittently. Exclusion of continuous monitoring, especially hemoglobin saturation, in these studies (table 2) may lead to underestimation of the incidence of clinically significant respiratory depression. However, even in these earlier studies, an incidence of respiratory depression, as defined by the authors, of approximately 10% was seen in many of them in the groups receiving transdermal fentanyl (table 2). A significant feature of the current findings was the relative restriction of respiratory depression to the 5–36-h period postoperatively. The occurrence of respiratory depression within this period corresponds with reports of other investigators. The mechanism of the respiratory depression in the current study probably is related to the slow development of analgesic plasma concentrations of fentanyl with the TTSF system and the requirement for larger doses of morphine in the PACU to control early postoperative pain. The additive effects of the two opioids and the continuing PCA morphine requirements are the most probable reason for the dose-
related increase in respiratory abnormalities and increased requirement for oxygen supplementation seen in the TTSF groups up to 36 h postoperatively. The decrease in respiratory depression after 36–48 h probably is related to the decrease in plasma fentanyl concentration at this time (fig. 6). An analysis of pharmacodynamic relationships between plasma fentanyl concentration and mean RR, SRR, and apnea revealed no correlation between any of the three respiratory parameters and plasma fentanyl concentration at any time when blood was sampled for plasma fentanyl (fig. 7). This indicates the high degree of variability in the occurrence of respiratory depression in the clinical setting due to factors discussed above and the difficulty in assigning a plasma fentanyl concentration at which respiratory depression occurs in the individual patient. Thus, it is possible that, in the postoperative period, for the individual patient, there may be as large a variability in plasma fentanyl concentration producing clinically significant respiratory depression as there is for the MEAC.\(^{24,26}\) This study also documented the relative safety of PCA morphine alone (placebo group) in terms of respiratory pattern and postoperative hypoxemia, although minimal alterations in these parameters were present secondary to postsurgical and anesthetic effects.\(^{39,40}\)

### Table 2. Transdermal Fentanyl: Comparative Studies—Respiratory Depression

<table>
<thead>
<tr>
<th>Study</th>
<th>Incidence</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borrman (1988)(^a)</td>
<td>0/20</td>
<td>1 patient: naloxone, TTS removed</td>
</tr>
<tr>
<td>Duthie (1989)(^b)</td>
<td>0/20</td>
<td>TTS removed</td>
</tr>
<tr>
<td>Gourlay (1989)(^11)</td>
<td>0/20</td>
<td>1 patient: naloxone; 2 patients: oxygen (mask)</td>
</tr>
<tr>
<td>Caplan (1989)(^a)</td>
<td>0/20</td>
<td>Patients aroused</td>
</tr>
<tr>
<td>Latach (1989)(^7)</td>
<td>0/20</td>
<td>No treatment</td>
</tr>
<tr>
<td>Boerner (1989)(^10)</td>
<td>0/12</td>
<td>Unknown treatment</td>
</tr>
<tr>
<td>Sevarino (1992)(^10)</td>
<td>0/32</td>
<td>1 patient: naloxone</td>
</tr>
<tr>
<td>Sandler (1994)</td>
<td>0/36</td>
<td>TTS removed, oxygen (mask)</td>
</tr>
</tbody>
</table>

Incidence = number of patients with clinically significant respiratory depression in each group; Active = TTS-fentanyl group; Size = TTS-fentanyl patch size; Placebo = placebo TTS group; treatment = treatment for respiratory depression; SRR = slow respiratory rate; ward = abnormal respiratory pattern in postanesthesia care unit; AP = apneic episodes.

In a large retrospective study, the incidence of severe respiratory depression in patients using PCA was 0.5%.\(^4,8\)

Most investigators found that the TTSF patch requires analgesic supplementation to provide effective pain relief, and the majority of studies used opioids as the supplementary analgesic agent. However, in the one study to date that used a nonsteroidal antiinflammatory drug as the supplementary analgesic agent, the incidence of respiratory depression (\(\text{Pa}_{\text{CO}_2}\), IRR) was low despite the use of a 75-\(\mu\)g/h TTSF patch.\(^7\) Similarly, in another study using the TTSF-75 patch in 50 patients, no clinically significant respiratory depression (IRR) was recorded when fentanyl was used as the supplementary analgesic.\(^4,4\) Both of these studies had the patch applied for 24 h only, and therefore, serum fentanyl concentration would have decreased after 24 h and would not summate with supplementary analgesic therapy to produce respiratory depression.

In contrast to early reports\(^4,6,9,13\) that hailed the TTSF patch as a major analgesic breakthrough for acute pain management, we conclude that the high incidence of respiratory depression under the conditions of the current study requires the TTSF system to be used only under closely monitored conditions for acute postoperative pain with resuscitation facilities close at hand. This applies to the small number of patients who will be able to use the TTSF patch as a sole analgesic system but will be particularly applicable if opioid or sedative supplementation is necessary. Thus, we do not recommend the routine use of the TTSF patch for acute pain control unless the above stipulations are met. Nevertheless, the TTSF system has several major advan-
tages (e.g., ease of use, high patient acceptability, increased analgesic effectiveness, nonlabor-intensive) that warrant further study to characterize other possible uses. Investigation into the use of the TTSF patch as a component of a multimodal analgesic system (i.e., in conjunction with an α agonist and a nonsteroidal anti-inflammatory drug) may provide an effective postoperative analgesic regimen. In addition, in the treatment of chronic cancer pain, the advantages of the TTSF patch combined with the system’s sustained drug release profile make it useful. This is evidenced by the fact that TTSF is used as a highly effective analgesic for chronic cancer pain and is approved for this use in several countries.

References